X

Dishman Carbogen Amcis Ltd Stock Analysis

Small Cap
Evaluated by 559 users | BSE: 540701 | NSE: DCAL |
Pharmaceuticals & Drugs

Incorporated in 1983, Dishman Carbogen Amcis Limited (DCAL) started out as a manufacturer of quaternary ammonium and phosphate compounds. Having ventured into the CRAMS space in India, the company soon became one of the fastest growing companies. Today, the...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Dishman Carbogen Amcis Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good
Value Creation
 Mar'10Mar'11Mar'12Mar'13Mar'14Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Capital Employed 0000003.11%3.33%4.17%3.57%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 0000001,7141,6952,0592,044
Y-o-Y Gr. Rt.-NANANANANANA-1.1%21.5%-0.7%
Adjusted EPS (Rs.) 000000010.2413.8412.28
Y-o-Y Gr. Rt.-NANANANANANANA35.2%-11.3%
Book Value per Share (Rs.) 0000000316.44333.28365.69
Adjusted Net Profit 000000145165223193
Net Op. Cash Flow (Rs. Cr.) 000000303226282585
Debt to Cash Flow from Ops 0000003.144.833.71.8
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Dishman Carbogen Amcis Ltd. should be analysed on a Consolidated basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales NANA6%-0.7%
Adjusted EPS NANANA-11.3%
Book Value per Share 0009.7
Share Price - - -28.7% 77%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'10Mar'11Mar'12Mar'13Mar'14Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Equity (%) 0000003.023.334.263.47
Operating Profit Margin (%) 00000026.6326.8627.9326.43
Net Profit Margin (%) 0000008.429.7510.859.43
Debt to Equity 000000238.620.210.190.18
Working Capital Days 0000000339308334
Cash Conversion Cycle 0000000139127144
Entity Percentage Holding
Promoters 61.93%
Institutions 15.72%
Non-Institutions 22.35%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

MoneyWorks4Me analysed the past 10-year performance of Dishman Carbogen Amcis Ltd and arrived at the following conclusion:

Past 10 year's financial track record indicates that Dishman Carbogen Amcis Ltd is a average quality company. However, for specific investment actions please connect with your investment advisor.

Data is not available for this company.

Data is not available for this company

Incorporated in 1983, Dishman Carbogen Amcis Limited (DCAL) started out as a manufacturer of quaternary ammonium and phosphate compounds. Having ventured into the CRAMS space in India, the company soon became one of the fastest growing companies. Today, the company is a leading global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up, and manufacturing services.

The

Incorporated in 1983, Dishman Carbogen Amcis Limited (DCAL) started out as a manufacturer of quaternary ammonium and phosphate compounds. Having ventured into the CRAMS space in India, the company soon became one of the fastest growing companies. Today, the company is a leading global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up, and manufacturing services.

The company aids drug innovators for development and process optimization for novel drug molecules in various stages of the development process. Once the innovative molecules are approved, the company further explore the possibility of large scale commercial supply tie-ups. The company is generating a healthy pipeline of contract manufacturing opportunities commensurate to the growing revenue base of manufacturing. Its robust business model is capable of sustaining growth, with CRAMS being the focal point of all its strategic efforts.

Business area of the company

The company is a fully integrated CRAMS player working with global pharmaceutical innovators. It has a global presence with development and manufacturing facilities across Europe, India, and China. It provides end-to-end, integrated, high-value, niche CRAMS offering, right from process research & development to late-stage clinical and commercial manufacturing facilities along with the supply of Active Pharmaceutical Ingredients (API) to innovator pharmaceutical companies.

Products and services

  • CRAMS
  • Vitamin D & Analogues
  • Disinfectants
  • Highly Potent API Supply
  • Niche Generic API
  • Speciality Chemicals

History and Milestones

  • 1983: Incorporation of Dishman Pharmaceutical and Chemicals Limited.
  • 1989: Commencing production of Phase Transfer Catalysts at Naroda facility.
  • 1995: Entered into a JV with Schutz & Co. for manufacturing Chlorhexidine and Derivatives for European market.
  • 1996: Commencement of Bavla facility for Bulk Intermediates.
  • 2001: First commercial contract manufacturing agreement signed with a major western pharmaceutical company.
  • 2004: Came out with an IPO on Indian stock exchanges.
  • 2005: Acquisition of Synprotec - DCR (now known as CARBOGEN AMCIS Ltd, UK).
  • 2006: Acquisition of CARBOGEN AMCIS - a Swiss based CRAMS player.
  • 2007: Acquisition of Solvay Pharmaceuticals’ Vitamins and Chemicals business (now known as CARBOGEN AMCIS BV).
  • 2010: Commenced Dishman Shanghai manufacturing facility.
  • 2012: Acquisition of Riom (France) - CARBOGEN AMCIS SAS.
  • 2014: Acquisition of Vionnaz (CH) site - CARBOGEN AMCIS.
  • 2017: Change of name of the parent to Dishman Carbogen Amcis Limited, reinforcing the synergies between Dishman and Carbogen Amcis brands.
  • 2020: Global Reorganization of Roles and Responsibilities of the Management Team.
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback